Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Rhea-AI Summary
Harrow (Nasdaq: HROW) reported three study presentations on IHEEZO and BYOOVIZ at the ASRS 2026 Annual Meeting, adding to clinical and real‑world evidence for its retina portfolio. According to Harrow, an interim, investigator‑initiated randomized study in 150 intravitreal injection patients comparing IHEEZO with subconjunctival lidocaine showed early trends toward less post‑procedure pain, improved post‑injection experience, and fewer ocular symptoms over 24 hours in the IHEEZO group.
Harrow continues enrolling QUELL, a prospective, randomized, multicenter IHEEZO trial in about 236 subjects under an active IND, with topline data expected in Q4 2026. A separate retrospective real‑world analysis of nearly 20,000 injections found no evidence that IHEEZO’s low‑viscosity gel formulation increased endophthalmitis risk versus a legacy tetracaine/povidone‑iodine regimen. Samsung Bioepis also presented interim findings from a large post‑marketing BYOOVIZ surveillance study, with full results being announced jointly with Harrow.
Positive
- None.
Negative
- None.
Market reaction after clinical data: HROW -4.72% in the Jul 20 session
In the Jul 20 session, HROW declined 4.72%, reflecting a moderate negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 01 | BYOOVIZ launch | Positive | +1.3% | U.S. commercial launch of FDA-approved BYOOVIZ biosimilar across retinal indications |
| Jul 01 | BYOOVIZ relaunch | Positive | +1.3% | Samsung Bioepis partnership relaunched BYOOVIZ in the United States |
| Jun 10 | VERKAZIA relaunch | Positive | +7.3% | VERKAZIA relaunch addressed pediatric vernal keratoconjunctivitis treatment needs |
| May 27 | Conference presentation | Neutral | +0.8% | Management scheduled a presentation at William Blair's annual growth stock conference |
| May 11 | Q1 earnings report | Negative | -23.7% | Q1 revenue and net-loss results were accompanied by reiterated 2026 guidance |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive product and commercial announcements were associated with positive 24-hour reactions, while the Q1 2026 earnings release had a -23.69% reaction.
Key Terms
biosimilar medical
investigational new drug (ind) regulatory
endophthalmitis medical
intravitreal injection medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel
“ASRS is one of the premier scientific meetings in retina, and we're excited to share data that continues to strengthen the foundation supporting our growing retina franchise,” said Mark L. Baum, Chief Executive Officer of Harrow. “We believe durable commercial success is built on strong clinical evidence, generated before FDA-approval, and then robust supportive data sets subsequently produced. These studies further expand the evidence supporting IHEEZO while adding to the growing body of real-world experience for BYOOVIZ, reflecting our long-term commitment to retina specialists and the patients they treat.”
One presentation highlighted interim findings from an investigator-initiated, prospective, randomized study of 150 patients comparing IHEEZO versus subconjunctival lidocaine. While these preliminary data represent an early look at the data, investigators observed encouraging trends toward less post-procedure pain, a better post-injection patient experience, and fewer ocular symptoms through 24 hours following intravitreal injection among patients treated with IHEEZO. Harrow believes these early findings provide an encouraging signal supporting further investigation in a larger patient population.
Importantly, Harrow continues to enroll QUELL, a prospective, randomized, multi-center clinical trial of approximately 236 subjects that is being conducted under an active Investigational New Drug (IND) application. QUELL is designed to generate robust clinical evidence evaluating post-injection pain, patient experience, procedural performance, and safety in a substantially larger patient population, with topline data expected in the fourth quarter of 2026.
Another real-world study retrospectively evaluated whether IHEEZO's proprietary low-viscosity gel formulation interferes with antisepsis when used with chlorhexidine before intravitreal injection. Across nearly 20,000 injections, investigators observed no evidence of an increased endophthalmitis risk compared with a legacy tetracaine/povidone-iodine preparation. Although retrospective and not intended to demonstrate statistical superiority, the findings provide further confidence that physicians can realize the patient-experience benefits of IHEEZO's low-viscosity gel formulation without introducing additional procedural risk associated with antisepsis.
“These studies help build the scientific foundation supporting IHEEZO,” said Amir Shojaei, Chief Scientific Officer of Harrow. “The early interim randomized data suggest the potential to improve the patient experience, while the large real-world analysis provides reassuring evidence regarding procedural safety. We look forward to completing enrollment in QUELL, which we believe will provide the most comprehensive evaluation of IHEEZO in retina to date.”
Finally, Samsung Bioepis presented interim findings from a large-scale, real-world post-marketing surveillance study of BYOOVIZ. Full results from this study are being announced jointly with Samsung Bioepis today.
“Between the continued expansion of the clinical evidence supporting IHEEZO, the recent launch of BYOOVIZ, and the ongoing growth of our retina franchise, we believe Harrow is increasingly well-positioned as a trusted long-term partner to retina specialists,” Baum concluded. “We appreciated the opportunity to engage with physicians throughout ASRS and look forward to sharing additional updates later this year.”
IHEEZO® (chloroprocaine hydrochloride ophthalmic gel)
INDICATIONS AND USAGE
IHEEZO is an ester anesthetic indicated for ocular surface anesthesia.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
- IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of
this preparation
WARNINGS AND PRECATIONS
- Not for Injection or Intraocular Administration.
- Corneal Injury Due to Insensitivity.
- Corneal Opacification
- For Administration by Healthcare Provider: IHEEZO is not intended for patient self-administration
ADVERSE REACTIONS
- Most common adverse reaction is mydriasis (approximately
25% )
Please see full Prescribing information
BYOOVIZ® (ranibizumab-nuna) injection, for intravitreal use is a biosimilar to LUCENTIS (ranibizumab injection)
INDICATIONS AND USAGE
BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Myopic Choroidal Neovascularization (mCNV)
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
- Ocular or periocular infections
- Hypersensitivity
WARNINGS AND PRECAUTIONS
- Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection
- Increases in intraocular pressure (IOP) have been noted both pre- and post intravitreal injection
- There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors
ADVERSE REACTIONS
- The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP
Please see full Prescribing Information
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contacts:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890
i Byooviz is a trademark of Samsung Bioepis Co., Ltd.
ii Lucentis is a trademark of Genentech, Inc.
